Asia Pacific Cardiometabolic Diseases Market

Market Introduction

The cardiometabolic disease is characterized by a group of abnormalities and symptoms that raise the risk of individuals developing cardiovascular disease. Hypertension, obesity, insulin resistance, dyslipidemia, poor cholesterol profile (LDL), and glucose tolerance are some of the symptoms. Individuals suffering from cardiometabolic syndrome are prone to several other life-threatening diseases such as type 2 diabetes, stroke, coronary artery disease (CAD), cardiovascular disease (CVD), and many others.

Moreover, the increasing prevalence of cardiometabolic diseases is expected to bolster the market growth during the forecast period. However, underdiagnosis of CVDs in low- and middle-income countries (LMICs) limits the growth of the Asia Pacific cardiometabolic diseases market.

The supply chain disruptions and the massive demand for efficient treatments for the therapy of COVID-19 have put the healthcare research industry in a crucial situation in the Asia Pacific region. Prohibitive measures have been taken to control the spread of this pandemic. COVID-19 pandemic has broadly affected those economies in the Asia Pacific region. Countries such as India (31,769,132), Japan (956,407), China (93,289), South Korea (203,926) were adversely affected by the pandemic. The socioeconomics were severely affected, rising in negative inflation, GDPs, and a regional unemployment surge. Recently, patients with both hypertension and obesity have been increasing in Japan. These patients are at exceptionally high risk for severe disease in COVID-19 and thus need careful observation and intensive treatment. Comparable to hypertension, the definition of obesity is not constant among studies/countries, which requires consideration. However, it is essential to note that the therapeutic mechanism of CCB against COVID-19 still awaits further investigation and randomized controlled clinical trials.

Market Overview and Dynamics

The Asia Pacific cardiometabolic diseases market is projected to reach US$ 28,953.2 million by 2028 from US$ 21,091.3 million in 2021; it is anticipated to grow at a CAGR of 4.6% from 2021 to 2028. Cardiometabolic diseases (CMDs) are one of the leading causes of death worldwide. These diseases are mainly caused by an unhealthy lifestyle, physical inactivity, smoking, and an unhealthy diet. CMDs include cardiovascular diseases (CVDs), diabetes mellitus, and chronic renal failure. Most cardiovascular diseases can be prevented by addressing behavioural risk factors, such as tobacco intake, unhealthy dietary choices, obesity, physical inactivity, and alcohol consumption. Diabetes is one of the life-threatening chronic diseases with no functional cure. It leads to various complications and increases the overall risk of premature death. Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are the major complications associated with diabetes. There is a rise in the number of people having one or more CMDs due to increasing smoking, lack of exercise, alcohol consumption, and unhealthy food habits. The increasing prevalence of obesity is giving rise to the patient base suffering from CMDs as well. With this rapid upswing in the prevalence of CMDs, the need for appropriate cardiometabolic disease treatments has skyrocketed, resulting in tremendous growth of the Asia Pacific cardiometabolic diseases market.

Key Market Segments

In terms of type, the cardiovascular disease segment accounted for the largest share of the Asia Pacific cardiometabolic diseases market in 2020. In terms of treatment, the ACE inhibitors segment accounted for the largest share of the Asia Pacific cardiometabolic diseases market in 2020. In terms of dosage, the tablet segment accounted for the largest share of the Asia Pacific cardiometabolic diseases market in 2020. In terms of route of administration, the oral segment accounted for the largest share of the Asia Pacific cardiometabolic diseases market in 2020. In terms of end user, the hospital segment accounted for the largest share of the Asia Pacific cardiometabolic diseases market in 2020. Further, based on distribution channel, the hospital pharmacy segment held the largest market share in 2020.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the cardiometabolic diseases market in Asia Pacific are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Eli Lilly and Company., Bayer AG, Novartis AG, Boehringer Ingelheim International Gmbh, Novo Nordisk A/S, AstraZeneca, Cardax Inc., and Kowa Company, Ltd.

Reasons to Buy Report

• To understand the Asia Pacific cardiometabolic diseases market landscape and identify market segments that are likely to guarantee a strong return
• To comprehend the ever-changing market landscape and stay ahead in competition
• To efficiently plan merger and acquisition, and partnership deals in the Asia Pacific cardiometabolic diseases market by identifying segments with the most promising probable sales
• To make knowledgeable business decisions from perceptive and comprehensive analysis of the market performance of various segments
• To obtain market revenue forecast of the Asia Pacific cardiometabolic diseases market based on various segments for the period 2021–2028 

ASIA PACIFIC CARDIOMETABOLIC DISEASES MARKET SEGMENTATION

By

• Cardiovascular disease (CVD)
• Type 2 diabetes
• Hypertension
• Obesity 

By Treatment

• ACE inhibitors
• Diuretics
• Glucophage
• Others 

By Dosage

• Tablet
• Injection 

By Route of Administration

• Oral
• Intravenous 

By End Users

• Hospital
• Clinic
• Homecare settings 

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Country

• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Rest of Asia Pacific

Companies Mentioned

• Eli Lilly and Company

  .

     
• Bayer AG                         
• Novartis AG                   
• Boehringer Ingelheim International Gmbh
• Novo Nordisk A/S       
• AstraZeneca                  
• Kowa Company, Ltd.
• Cardax, Inc.

Asia Pacific Cardiometabolic Diseases Strategic Insights

Strategic insights for the Asia Pacific Cardiometabolic Diseases provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific Cardiometabolic Diseases Report Scope

Asia Pacific Cardiometabolic Diseases Regional Insights

The geographic scope of the Asia Pacific Cardiometabolic Diseases refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.